NKTR News and Press, Nektar Therapeutics From 04/17/23

2023-04-17 17:46:12 ET Nektar Therapeutics ( NASDAQ: NKTR ) will implement a reprioritization and cost restructuring plan that also involves a new pipeline focus on immunology. The biotech will also cut its San Francisco-based workforce by 60%, leaving it with ~55 emp...

Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan PR Newswire -- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in diffuse large B-cell ly...

2023-04-10 14:58:39 ET Investing in penny stocks can be a high-risk, high-reward game. The lure of potentially making big profits in a short amount of time can be tempting. But it’s important to understand the risks involved. Penny stocks are typically low-priced, small-cap stock...

2023-04-05 11:48:12 ET What are penny stocks? This is probably a question you’re asking if you’re brand new to the stock market. The basic definition includes stocks trading for less than $5 and are typically associated with smaller start-up companies. However, that doesn ...

2023-04-03 10:43:36 ET Investors may find penny stocks under $1 an attractive option for trading. However, caution is critical when investing in these stocks. That’s simply because they come with inherent risks that can lead to significant losses if not approached carefully. One ...

Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 PR Newswire NEW YORK , March 29, 2023 /PRNewswire/ -- Crane Co. (NYSE:CR) will be added to th...

2023-03-29 17:24:32 ET Nektar Therapeutics ( NASDAQ: NKTR ) slipped 6.4% postmarket Wednesday following news that it would be removed from the S&P SmallCap 600 index. The stock is getting bumped as part of a cascade of moves tied to adding new Crane ( NYSE: CR ...

Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank PR Newswire SAN FRANCISCO , March 11, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirmin...

Nektar Therapeutics press release ( NASDAQ: NKTR ): Q4 GAAP EPS of -$0.32 beats by $0.13 . Revenue of $22.02M (-12.0% Y/Y) misses by $0.19M . Cash and investments in marketable securities at December 31, 2022, were approximately $505.0 million as compared to $798.8 mil...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results PR Newswire SAN FRANCISCO , Feb. 28, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, ...